Comparison of ESC and ACCF/AHA Guidelines for Oral Antiplatelet Treatment in the Management of Patients with Acute Coronary Syndrome

Ayhan Sarıtaş, Harun Güneş
Department of Emergency Medicine, Düzce University School of Medicine, Düzce, Turkey

Abstract

Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. New studies performed in recent years have led to the update of guidelines for the usage of antiplatelet agents (APA) in the treatment of ACSs. This paper aims to compare the European Society of Cardiology (ESC) and American Heart Association (ACCF/AHA) guidelines, by summarizing the key points, regarding the usage of oral APA in patients admitted to emergency departments due to ACS.

Keywords: Acute coronary syndrome, recommendations, aspirin, prasugrel, ticagrelor, clopidogrel

Introduction

Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. Antiplatelet agents (APA) act by inhibiting the cyclooxygenase enzyme (aspirin) and P2Y\textsubscript{12} receptor. The main features of P2Y\textsubscript{12} receptor inhibitors are listed in Table 1. New studies performed in recent years have led to the update of guidelines for the usage of APA in the treatment of ACSs. This paper aims to compare the European Society of Cardiology (ESC) (1, 2) and American Heart Association (ACCF/AHA) guidelines (3, 4), by summarizing the key points, regarding the usage of oral APA in patients admitted to emergency departments due to ACS. APA strategies that should be chosen in ST-segment elevation myocardial infarction (STEMI) and non–ST-segment elevation myocardial infarction (NSTEMI)/unstable angina (UA) pectoris cases were discussed under separate headings.

APA Treatment in STEMI

European Society of Cardiology (2) and AHA (4) guidelines on this subject were updated in 2012 and 2013, respectively. Both guidelines recommend the administration of aspirin as the first step (Class I), regardless of the treatment strategy chosen (i.e., fibrinolytic or percutaneous coronary intervention). Both guidelines also agree on the immediate initiation of dual antiplatelet therapy (a P2Y\textsubscript{12} inhibitor in addition to aspirin) (Class I). Drugs and dosages vary according to the chosen treatment strategy. Thus, the recommendations have been described separately with regard to treatment strategy. An initial aspirin dose of 150–500 mg and clopidogrel dose of 75 mg/day are recommended in patients for whom no reperfusion therapy is planned (2).

If fibrinolytic therapy is planned

Aspirin

ESC (Class IB)
- 150–500 mg oral loading dose (250 mg IV loading dose if oral ingestion is not possible)
- 75–100 mg/day maintenance dose

ACCF/AHA (Class IA)
- 162–325 mg oral loading dose
- 81–325 mg/day maintenance dose

P2Y\textsubscript{12} Receptor Inhibitors

Both guidelines recommend the use of clopidogrel in patients with STEMI for whom fibrinolytic therapy is planned. However, prasugrel and ticagrelor should not be used in such patients because the use of these agents has not been studied yet as an adjunctive treatment in fibrinolysis (2, 4).
**Table 1. Main features of P2Y12 receptor inhibitors (1)**

<table>
<thead>
<tr>
<th></th>
<th>Clopidogrel</th>
<th>Prasugrel</th>
<th>Ticagrelor</th>
<th>Cangrelor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemical class</strong></td>
<td>Thienopyridine</td>
<td>Thienopyridine</td>
<td>Cyclopentyl-triazolo-pyrimidine</td>
<td>Stabilized ATP analogue</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>Oral</td>
<td>Oral</td>
<td>Oral</td>
<td>Intravenous</td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td>300–600 mg bolus, 75 mg/day</td>
<td>60 mg bolus, 10 mg/day</td>
<td>180 mg bolus, 90 mg × 2/day</td>
<td>30 mcg/kg bolus, 4 mcg/kg/min inf.</td>
</tr>
<tr>
<td><strong>Receptor inhibition</strong></td>
<td>Irreversible</td>
<td>Irreversible</td>
<td>Reversible</td>
<td>Reversible</td>
</tr>
<tr>
<td><strong>Activation</strong></td>
<td>Prodrug</td>
<td>Prodrug</td>
<td>Direct-acting</td>
<td>Direct-acting</td>
</tr>
<tr>
<td><strong>Onset of action</strong></td>
<td>2–6 h</td>
<td>30 min</td>
<td>30 min</td>
<td>2 min</td>
</tr>
<tr>
<td><strong>Duration of effect</strong></td>
<td>3–10 days</td>
<td>7–10 days</td>
<td>3–5 days</td>
<td>1–2 h</td>
</tr>
<tr>
<td><strong>Withdrawal before surgery</strong></td>
<td>5 days</td>
<td>7 days</td>
<td>5 days</td>
<td>1 h</td>
</tr>
</tbody>
</table>

ESC and ACCF/AHA

**Clopidogrel (Class I)**
- 300 mg bolus (if age ≤75 years), 75 mg/day maintenance dose
- If the patient’s age is >75 years: 75 mg bolus, 75 mg/day maintenance dose

**If percutaneous coronary intervention is planned**

**Aspirin**
ESC (Class IB)
- 150–300 mg oral loading dose (80–150 mg IV loading dose if oral ingestion is not possible)
- 75–100 mg/day maintenance dose

ACCF/AHA
- 162–325 mg bolus (Class IB)
- 81–325 mg/day maintenance (Class IA)

**P2Y12 Receptor Inhibitors**
ESC
- Prasugrel (if there is no history of stroke/transient ischemic attack; age <75 years) (Class IB)
- Ticagrelor (Class IB)
- Clopidogrel: 600 mg bolus, 75 mg/day maintenance (if prasugrel and ticagrelor are contraindicated or not available) (Class IC)

ACCF/AHA
- All the three APAs are recommended as Class IB, contrary to European guidelines.
  - Clopidogrel: 600 mg bolus, 75 mg/day maintenance (Class IB)
  - Prasugrel (Class IB)
  - Ticagrelor (Class IB)

**If percutaneous coronary intervention is planned in patients who have been given fibrinolytic therapy previously**
ESC
Recommends the same P2Y12 receptor inhibitor dose as it is used in patients undergoing percutaneous coronary intervention

ACCF/AHA
In patients who have not taken clopidogrel loading dose previously

- Clopidogrel: 300 mg bolus if the patient is admitted within 24 h following fibrinolytic therapy (Class IC)
- Clopidogrel: 600 mg bolus if more than 24 h have passed following fibrinolytic therapy (Class IC)

It is not necessary to repeat the loading dose in patients who have been given a loading dose previously.

**APA Treatment in UA/NSTEMI**
Aspirin therapy significantly decreases the rates of mortality and reinfarction. Aspirin is recommended in the ESC and ACCF/AHA guidelines as it has been used for patients with STEMI (Class I). Aspirin should be administered as soon as possible following patient admission, if it is not contraindicated. A clopidogrel loading dose followed by maintenance doses should be administered to patients who cannot take aspirin due to hypersensitivity or gastrointestinal intolerance (Class IB). The usage of P2Y$_12$ receptor inhibitors together with aspirin provides an additive effect. Dual APA therapy is a Class IA recommendation in the ESC and ACCF/AHA guidelines.

**Aspirin**
ESC (Class IA)
- 150–300 mg oral loading dose
- 75–100 mg/day maintenance dose

ACCF/AHA (Class IA)
- 162–325 mg oral loading dose (75–162 mg if there is a high risk of hemorrhage)
- 81–162 mg/day maintenance dose

**P2Y$_12$ Receptor Inhibitors**
ESC
- Prasugrel (recommended in patients proceeding to percutaneous coronary intervention) (Class IB)
- Ticagrelor (recommended in patients who cannot receive prasugrel or ticagrelor) (Class IB)

ACCF/AHA
- Ticagrelor (Class IB)
- Cangrelor (Class IB)
- Ticagrelor in preference to clopidogrel in patients treated with an early invasive or an ischemia-guided strategy (Class IIaB)
- Prasugrel is recommended after the patient is taken to the laboratory, and the coronary anatomy is seen if the patient was not given a P2Y_12_ receptor inhibitor until he is taken to the laboratory (Class IB).

Prasugrel is contraindicated in patients ≥75 years of age or <60 kg of weight or have a history of stroke/transient ischemic attack. Besides, prasugrel should not be used in patients with an unknown coronary anatomy (Class IIIB).

Cangrelor, another P2Y_{12} receptor inhibitor, may be considered in patients who need to undergo percutaneous coronary intervention (Class IIbA). However, cangrelor is not approved by the European Medical Agency or the Federal Drug Administration. Thus, there is no specific recommendation for its usage.

**Conclusion**

The administration of aspirin as the first step is recommended for all patients with ACS. Since the usage of P2Y_{12} receptor inhibitors together with aspirin provides an additive effect, immediate initiation of dual antiplatelet therapy is recommended, too. A combination of an initial aspirin dose of 150–500 mg and clopidogrel dose of 75 mg/day is recommended in STEMI patients for whom no reperfusion therapy is planned. Clopidogrel is recommended in patients with STEMI for whom fibrinolytic therapy is planned. If percutaneous coronary intervention is planned in a STEMI patient, prasugrel, and ticagrelor are preferred over clopidogrel. A clopidogrel loading dose followed by maintenance doses should be given to patients with UA/NSTEMI who cannot take aspirin due to hypersensitivity or gastrointestinal intolerance. While choosing a P2Y_{12} receptor inhibitor for a patient with UA/NSTEMI, clopidogrel should be used only if the patient cannot take prasugrel or ticagrelor. Prasugrel should not be used in patients with a history of stroke/transient ischemic attacks or ≥75 years of age or <60 kg of weight. It should also be emphasized that prasugrel can only be used after the coronary anatomy is seen.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**References**